These projects are the easiest to receive funding! Data analysis of 139 global pharmaceutical R&D cooperation during the epidemic

The new crown spread of the epidemic in the world to shut down half the state, and in a short time hot field of biological medicine seems to be powerless, even if people are known as promising drug failed to turn things aroundBut the good news is, there are still a lot of concern for the fate of the company in difficult times to come forward and charged the epidemicIn this paper the statistical data collaboration over the past more than four months on the new crown anti-drug development, incomplete statistics a total of 139 publicly traded happened pen, seen from the time curve for the transaction at 3.1-4.18 of active cooperation, also happens to be a global epidemic outbreak curve the preceding paragraphNumbertransactional relationship with timein these transactions, the funds mainly from the cooperative enterprise rather than government funds accounted for 55% (76 transactions)For enterprise business profit it is clearly not possible to achieve maximum benefits in this epidemic, because investment in anti-drug development generated new crown uncertain future earningsAlthough the new outbreak of highly infectious crown, but lower death rate (mortality rate = 5%), and large-scale spread of the epidemic is obviously much shorter drug development cycle it is relative, and rely on the existing conditions in many countries have effective control live national epidemicDrug development is rational, and not significantly shorten the development cycle because of the epidemic, with the necessary development steps after the market had a high probability of significant long since disappeareddistributed transaction type body
regardless of the ultimate success of research and development, there are currently involved in research and development unit of drug treatment are worthy to be remembered and thanksgivingknown drug development investment is expensive, especially when the scarcity also reflects a race against timeAccording to public data to incomplete statistics, 278 enterprises and institutions involved in the statistics, the Johnson & Johnson and the US biomedical research Administration announced plans to spend $ 1 billion on research and development of new anti-drugs crown, the amount of cooperation had pulled amount of public R & D cooperation the first to hold the event; the universe's largest pharmaceutical companies Pfizer outdone, spent $ 748 million project BioNTech of vaccine introduction; large international pharmaceutical companies have force, but undoubtedly the most active player in US stocks biotechnology company VirBiotechnology, it met with GlaxoSmithKline, Samsung biological, Biogen and drug-ming of eight companies reached a cooperation platform for companies to highlight the technological strengthAccording to Vir said they have more binding and neutralizing coronavirus (eg SARS and MERS) fully human monoclonal antibody libraryThese antibodies are isolated from survivors of SARS infection in vivo, some of which monoclonal antibodies may respond to the new coronavirusAlthough many participants, but most are still in the early stages of development cooperation In this 139 cooperation can be divided into research and development, licensing, sponsorship, clinical trials, production, of which about 56% are in the early stages of development cooperation, about 9.3% of cooperation in clinical trials, the road ahead will be long Come cooperation object classification


in all areas of research and development, the most anticipated vaccines and antibodies After the early epidemic after a variety of hot rub magic pill, the new crown anti-viral drug discovery to return to reason, dismantling the subject of various cooperation to get the current vaccine developed fever (45%) mainly antibodies (20%) and small molecules (13%) followed cooperation under research and development division heat According to several institutions predict vaccine or come out in the next 12-18 months 2020 April 8, there were already 115 COVID-19 vaccine candidates in development, which can confirm the progress of the 73 have in the exploration or pre-clinical stage, five fastest progress of candidate vaccines have entered clinical stage China currently has more than COVID-19 vaccine approved to enter clinical trials, of which Chen Wei academician team of adenoviral vector vaccine approved in clinical studies, the vaccination was completed a clinical trial of the end of March, and on April 9 began recruiting volunteers Phase II clinical trials, the vaccine is COVID-19 varieties of the world's first clinical study start the second phase On April 12 soon afterwards, the State Food and Drug Administration approved the COVID-19 virus inactivated vaccine China, Wuhan Institute of Virology, Wuhan Institute of Biological Products Biological and Chinese Academy of Sciences a joint application to enter clinical trials; April 13, the national drug supervisor Bureau has approved Beijing Sinovac biotech Co., Ltd in Victoria developed inactivated vaccine clinical trials antibody drug development, development of neutralizing antibodies has also been high expectations Medrxiv preprint website May 7 released from the CDC director in China, Chinese Academy of Sciences Gao Fu team latest research COVID-19 prevention and control Team isolated four kinds of monoclonal antibodies, and shows the ability of the virus in vitro, can provide a structural basis for COVID-19 pharmaceutical and vaccine design Before that, Jimin credible, the sea is medicine, Shanghai Jun fact, Sino, platinum and pharmaceuticals, Chengdu Sheng Shijun Union and other bets in this direction have already made good progress although cooperation on research and development of new anti-virus crown in full swing, but the author there is deep concern After all, the number of projects funded is limited, worldwide, there are still a large number of self-financing launch a "retrograde" who assault the crown to the new virus in the absence of external funding situation, and the epidemic will eventually end of the day, these "retrograde "who pay in order to fight the epidemic spontaneous manner in which the authority has not yet digested propose solutions All items unrealistic pay in full by the society, and there is no background may ignore these "retrograde person" may not Although the new crown to join the anti-epidemic is spontaneous behavior, but their heart is beginning to security of the whole society, how to deal with their R & D investment is therefore produced thought-provoking questions, after all outbreaks in the past even the best products out of the market If this problem is not handled properly, may affect the values ​​of society, the author thus very worried about whether the next epidemic comes, there are so many "retrograde" as the fighting us